Mechanisms of right heart failure—A work in progress and a plea for failure prevention

Pulmonary Circulation

Volumn 3, Issue 1, 2013, Pages 137-143

  Voelkel, Norbert F ^a   Gomez Arroyo, Jose ^a   Abbate, Antonio ^a   Bogaard, Harm J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890253177     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.109957     Document Type: Article

References (51)

1. Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, et al. The pressure-overloaded right ventricle in pulmonary hypertension. Chest, 1998;114(1 Suppl):101S-6S.
2. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, et al. Right Ventricular Function and Failure: Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Circulation 2006;114:1883-91.
3. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009;135: 794-804.
4. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 2008;117:1717-31.
5. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 2008;117:1436-48.
6. Gómez A, Bialostozky D, Zajarias A, Santos E, Palomar A, Martínez ML, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 2001;38:1137-42.
7. Meyer P, Desai RV, Mujib M, Feller MA, Adamopoulos C, Banach M, et al. Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. Int J Cardiol 2012;155:120-5.
8. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011;20:243-53.
9. Voelkel NF, Natarajan R, Drake JI, Bogaard HJ. Right Ventricle in Pulmonary Hypertension. Compr Physiol 2011;1:525-40.
10. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, et al. Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats. Am J Respir Crit Care Med 2010;182:652-60.
11. Voelkel NF. The Wide Spectrum of Pulmonary Vascular Diseases: “The Sick Lung Circulation”. In: Voelkel NF, Editor. Pulmonary Hypertension The Presence and Future. USA: People’s Medical Publishing House; 2011.
12. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010;138:1234-9.
13. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011;58:2511-9.
14. Voelkel NF, Reeves JT. Primary Pulmonary Hypertension. In: Moser KM, editor. Pulmonary Vascular Diseases, New York: Marcel Dekker, Inc., 1979. p. 573-6.
15. Lang I, Kneussl M, Frank H, Mlczoch J. [Long-term follow-up of pulmonary hypertension of unknown etiology]. Pneumologie 1990;44:913-4.
16. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15:100-5.
17. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120:1951-60.
18. van Wolferen SA, Marcus JT, Westerhof N, Spreeuwenberg MD, Marques KM, Bronzwaer JG, et al. Right coronary artery flow impairment in patients with pulmonary hypertension. Eur Heart J 2008;29:120-7.
19. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, et al. Progression from compensated hypertrophy to failure in the pressureoverloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-91.
20. Elsässer A, Decker E, Kostin S, Hein S, Skwara W, Müller KD, et al. A self-perpetuating vicious cycle of tissue damage in human hibernating myocardium. Mol Cell Biochem 2000;213:17-28.
21. Handoko ML, de Man FS, Happé CM, Schalij I, Musters RJ, Westerhof N, et al. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 2009;120:42-9.
22. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007;13:952-61.
23. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O, et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A 2008;105:282-7.
24. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, et al. Heart and lung VEGF mRNA expression in rats with monocrotalineor hypoxia-induced pulmonary hypertension. Am J Physiol 1998;275: H1948-56.
25. Watts JA, Zagorski J, Gellar MA, Stevinson BG, Kline JA. Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol 2006;41:296-307.
26. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012;485:251-5.
27. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, et al. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 1999;103:R23-9.
28. Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, et al. Altered microRNA Processing in Heritable Pulmonary Arterial Hypertension: an Important Role for Smad-8. Am J Respir Crit Care Med 2011;184:1400-8.
29. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012;185:409-19.
30. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011;208:535-48.
31. Reddy S, Zhao M, Hu DQ, Fajardo G, Hu S, Ghosh Z, et al. Dynamic microRNA Expression During the Transition from Right Ventricular Hypertrophy to Failure. Physiol Genomics 2012;44:562-75.
32. Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating microRNAs: Novel biomarkers for cardiovascular diseases. J Mol Med (Berl), 2011;90: 865-75.
33. Gladka MM, da Costa Martins PA, De Windt LJ. Small changes can make a big difference-microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol 2012;52:74-82.
34. Wang K, Lin ZQ, Long B, Li JH, Zhou J, Li PF. Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a. J Biol Chem 2012;287: 589-99.
35. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure. Circulation 2011;124:1537-47.
36. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:1239-47.
37. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med 2007;356:1140-51.
38. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004;110:894-6.
39. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle. J Mol Med (Berl) 2010;88:47-60.
40. Can MM, Kaymaz C, Tanboga IH, Tokgoz HC, Canpolat N, Turkyilmaz E, et al. Increased right ventricular glucose metabolism in patients with pulmonary arterial hypertension. Clin Nucl Med 2011;36:743-8.
41. Oikawa M, Kagaya Y, Otani H, Sakuma M, Demachi J, Suzuki J, et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 2005;45:1849-55.
42. Wong YY, Ruiter G, Lubberink M, Raijmakers PG, Knaapen P, Marcus JT, et al. Right ventricular failure in idiopathic pulmonary arterial hypertension is associated with inefficient myocardial oxygen utilization. Circ Heart Fail 2011;4:700-6.
43. Gomez-Arroyo JG, Mizuno S, Drake JI, Al Hussaini AA, Farkas L, Farkas D, et al. Adrenergic Receptor Blocker Improves Metabolic Remodeling in Experimental Right Ventricular Failure Due to Pulmonary Hypertension. Am J Respir Crit Care Med 2011;183:A2520.
44. Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, dos Remedios CG et al. Metabolic Remodeling in Right Heart Failure is Associated with Abnormal Mitochondrial Biogenesis. Am J Respir Crit Care Med 2012;185:A3455.
45. Abel ED, T Doenst. Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophy. Cardiovasc Res 2011;90:234-42.
46. Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle. J Mol Med (Berl) 2012;90:31-43.
47. Finck BN, Kelly DP. PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease. J Clin Invest 2006;116:615-22.
48. Benit P, Rustin P. Changing the diet to make more mitochondria and protect the heart. Circ Res 2012;110:1047-8.
49. Krebs P, Fan W, Chen YH, Tobita K, Downes MR, Wood MR, et al. Lethal mitochondrial cardiomyopathy in a hypomorphic Med30 mouse mutant is ameliorated by ketogenic diet. Proc Natl Acad Sci U S A 2011;108:19678-82.
50. Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, Hall-Porter M, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res 2009;104:265-75, 11p following 275.
51. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest 2010;120:4141-54.